Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Somnomed.
RELATED STOCKHEAD STORIES
Director Trades
Directors’ Trades: As Nuix recovers from last month’s lows, one director made a $501,180 buy
Health & Biotech
ScoPo’s powerplays: It’s been ‘like a waterfall of information’ hitting us daily
Health & Biotech
SomnoMed taps tech for new board hires, posts full-year profit
Experts
Scopo’s powerplays: Investors love a result, until they don’t
News
What ASX investors should look for in a COVID-19 earnings season
Food & Agriculture
Economic recovery post-COVID, the five sectors that will lead the charge
Health & Biotech
These are the life sciences small caps almost unscathed by COVID-19
Experts
Scopo’s powerplays: It just won’t go down!
Health & Biotech
The health stocks still taking a hit from COVID-19
Health & Biotech
Check up: Diarrhoea and the FDA are lifting share prices
Health & Biotech
Check up: Sometimes no news is good news
Experts
Scopo’s health powerplays: You’re all going to the pot, literally
Health & Biotech
Night terrors are over for sleep stock Somnomed
Director Trades
Directors Trades: This anti-snoring device maker needed capital to survive COVID-19; one director put in $3.7m
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Health: Somnomed spins fairytale of a sleep cure in half-year results
Health & Biotech
